KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Leases (2020 - 2026)

Biocryst Pharmaceuticals filings provide 6 years of Operating Leases readings, the most recent being $8.6 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 8.17% to $8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.6 million, a 8.17% increase, with the full-year FY2025 number at $8.6 million, up 8.17% from a year prior.
  • Operating Leases hit $8.6 million in Q4 2025 for Biocryst Pharmaceuticals, up from $8.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $10.0 million in Q3 2023 to a low of $4.0 million in Q4 2022.
  • Median Operating Leases over the past 5 years was $8.3 million (2022), compared with a mean of $7.6 million.
  • Biggest five-year swings in Operating Leases: tumbled 32.46% in 2022 and later soared 108.34% in 2023.
  • Biocryst Pharmaceuticals' Operating Leases stood at $6.0 million in 2021, then tumbled by 32.46% to $4.0 million in 2022, then skyrocketed by 108.34% to $8.4 million in 2023, then dropped by 5.55% to $7.9 million in 2024, then grew by 8.17% to $8.6 million in 2025.
  • The last three reported values for Operating Leases were $8.6 million (Q4 2025), $8.4 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.